Pfizer wasn’t the only pharma interested in buying Metsera, and it also didn’t pay as much as the obesity biotech’s board desired, according to new regulatory documents outlining their $4.9 billion M&A deal disclosed last month. The New York pharma giant, which was seen as falling badly behind after prior obesity drug setbacks, ended up raising its offer a few times throughout its months-long discussions with Metsera, according to the filing. Pfizer ended up winning the deal with an offer that could be worth as much as $70 per share — compared with a rival offer of as much as $91 per share, but that was seen as less certain to close.
Read the full article: Metsera Got Less Than It Wanted from Pfizer in Long-Awaited Obesity Biotech Acquisition //
Source: https://endpoints.news/metsera-got-less-than-it-wanted-from-pfizer-in-long-awaited-obesity-biotech-acquisition/